PT2250280E - Utilizações terapêuticas da gelsolina na insuficiência renal - Google Patents

Utilizações terapêuticas da gelsolina na insuficiência renal Download PDF

Info

Publication number
PT2250280E
PT2250280E PT09703176T PT09703176T PT2250280E PT 2250280 E PT2250280 E PT 2250280E PT 09703176 T PT09703176 T PT 09703176T PT 09703176 T PT09703176 T PT 09703176T PT 2250280 E PT2250280 E PT 2250280E
Authority
PT
Portugal
Prior art keywords
gelsolin
renal failure
therapeutic uses
therapeutic
renal
Prior art date
Application number
PT09703176T
Other languages
English (en)
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital, Beth Israel Hospital filed Critical Gen Hospital Corp
Publication of PT2250280E publication Critical patent/PT2250280E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT09703176T 2008-01-25 2009-01-23 Utilizações terapêuticas da gelsolina na insuficiência renal PT2250280E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2378908P 2008-01-25 2008-01-25

Publications (1)

Publication Number Publication Date
PT2250280E true PT2250280E (pt) 2015-03-04

Family

ID=40901583

Family Applications (2)

Application Number Title Priority Date Filing Date
PT131862492T PT2708603T (pt) 2008-01-25 2009-01-23 Utilizações em diagnóstico e terapia da gelsolina na insuficiência renal
PT09703176T PT2250280E (pt) 2008-01-25 2009-01-23 Utilizações terapêuticas da gelsolina na insuficiência renal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT131862492T PT2708603T (pt) 2008-01-25 2009-01-23 Utilizações em diagnóstico e terapia da gelsolina na insuficiência renal

Country Status (10)

Country Link
US (2) US9575072B2 (pt)
EP (2) EP2708603B1 (pt)
JP (2) JP5778425B2 (pt)
CA (2) CA2749985C (pt)
DK (2) DK2250280T3 (pt)
ES (2) ES2531827T3 (pt)
HU (1) HUE032875T2 (pt)
PL (2) PL2708603T3 (pt)
PT (2) PT2708603T (pt)
WO (1) WO2009094194A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CN1980694B (zh) 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
ES2651619T3 (es) * 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
EP2153234A2 (en) * 2007-05-11 2010-02-17 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
PL2708603T3 (pl) 2008-01-25 2017-12-29 Beth Israel Deaconess Medical Ct Inc Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek
US20100049672A1 (en) * 2008-08-25 2010-02-25 Critical Biologics Corporation Methods for Reducing Sample Size of Clinical Trials
ES2356217B1 (es) * 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
TW201601741A (zh) * 2013-09-09 2016-01-16 品特生物療法有限公司 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑
CN104004780A (zh) * 2014-06-17 2014-08-27 南京大学 一种人胞质凝溶胶蛋白的表达纯化方法
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
US20220339243A1 (en) * 2019-06-21 2022-10-27 Bioaegis Therapeutics Inc. Compositions and synergistic methods for treating infections
CN116322737A (zh) * 2020-05-04 2023-06-23 生物保护医疗公司 用于治疗衰弱的包含凝溶胶蛋白的组合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) * 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
WO1991015770A1 (en) * 1990-04-11 1991-10-17 The General Hospital Corporation Therapeutic uses of actin-binding compounds
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
WO1991017170A1 (en) 1990-05-04 1991-11-14 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5360350A (en) * 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
AU4801393A (en) 1992-08-03 1994-03-03 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
WO1994008049A1 (en) 1992-10-01 1994-04-14 The General Hospital Corporation Functional assay for tumor suppressor genes
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5804427A (en) * 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) * 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
WO1998004589A2 (en) 1996-07-30 1998-02-05 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
DE69716460T2 (de) * 1996-12-04 2003-06-26 Renovo Ltd Wundheilung und behandlung von fibrose
PT1003501E (pt) * 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
ES2299436T3 (es) 1999-10-06 2008-06-01 ABBOTT GMBH & CO. KG Composicion que comprende un inhibidor de tnf-alfa y un antagonista de receptor de integrina alfavbeta3.
AU2002225219A1 (en) 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
CN1507354A (zh) 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
IL159771A0 (en) 2001-07-09 2004-06-20 Combinatorx Inc Combinations for the treatment of inflammatory disorders
WO2003020213A2 (en) 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2004035008A2 (en) 2002-02-06 2004-04-29 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
AU2003226401A1 (en) 2002-04-16 2003-11-03 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US20050048574A1 (en) 2003-03-14 2005-03-03 Kantor Aaron B. Biomarkers for diagnosing rheumatoid arthritis
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
JP2007521336A (ja) 2003-12-22 2007-08-02 リジェナークス・バイオファーマシューティカルズ・インコーポレイテッド 反応性化学物質、生物学的物質、もしくは毒素に対する、生物学的もしくは免疫学的応答を、処理もしくは防止する方法
WO2005085859A1 (en) 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
CN1980694B (zh) 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
AR049200A1 (es) 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
DK1929297T3 (da) 2005-09-29 2013-03-04 Caprion Proteomics Usa Llc Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
ES2651619T3 (es) * 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
PL2708603T3 (pl) 2008-01-25 2017-12-29 Beth Israel Deaconess Medical Ct Inc Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek
KR101568323B1 (ko) 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Also Published As

Publication number Publication date
PL2708603T3 (pl) 2017-12-29
PT2708603T (pt) 2017-07-20
EP2250280B1 (en) 2014-12-03
HUE032875T2 (en) 2017-11-28
PL2250280T3 (pl) 2015-06-30
EP2708603B1 (en) 2017-04-19
ES2531827T3 (es) 2015-03-20
US20170189483A1 (en) 2017-07-06
WO2009094194A2 (en) 2009-07-30
US9575072B2 (en) 2017-02-21
DK2250280T3 (en) 2015-03-09
JP2011510327A (ja) 2011-03-31
JP2015121550A (ja) 2015-07-02
US20090258830A1 (en) 2009-10-15
CA3080273C (en) 2022-11-22
WO2009094194A3 (en) 2010-01-21
CA2749985C (en) 2020-07-07
DK2708603T3 (en) 2017-08-14
JP5778425B2 (ja) 2015-09-16
EP2250280A2 (en) 2010-11-17
EP2250280A4 (en) 2011-02-16
ES2634263T3 (es) 2017-09-27
JP6042915B2 (ja) 2016-12-14
EP2708603A1 (en) 2014-03-19
CA3080273A1 (en) 2009-07-30
US10272136B2 (en) 2019-04-30
CA2749985A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
PL2250280T3 (pl) Terapeutyczne zastosowania gelsoliny w niewydolności nerek
PT2209893E (pt) Uso de aptâmeros em proteómica
GB0802457D0 (en) Improvements in or relating to stairlifts
GB0907009D0 (en) Improvements in or relating to composite structures
HK1159104A1 (zh) 慢性腎功能衰竭處置劑
HK1150156A1 (en) Improvements in or relating to inhalers
GB0708215D0 (en) Improvements in or relating to building components
GB0709551D0 (en) Improvements in or relating to stairlifts
GB2463734B (en) Improvements in or relating to stairlifts
GB0810840D0 (en) Improvements in or relating to stairlifts
GB0804752D0 (en) Improvements in or relating to wall-ties
GB0718710D0 (en) Improvements in or relating to stairlifts
GB0800459D0 (en) Improvements in or relating to inhalers
GB2457767B (en) Improvements in or relating to stairlifts
GB0821983D0 (en) Improvements in or relating to structural members
GB201111519D0 (en) Improvements in or relating to cubicle construction
GB2488051B (en) Improvements in or relating to stairlifts
GB0903527D0 (en) Improvements in hinges
GB201001898D0 (en) Improvements in or relating to urinal systems
GB0710359D0 (en) Improvements in or relating to building components
GB0802813D0 (en) Improvements in or relating to laminate structures
GB0807582D0 (en) Improvements in or relating to laminate structures
GB2475115B (en) Improvements in or relating to furniture
GB0823605D0 (en) Isb curative
GB0806840D0 (en) Improvements in or relating to composite structures